EC approves expanded use of Stelara for moderately to severely active ulcerative colitis

The European Commission on Wednesday approved the expanded use of Stelara for adults with moderately to severely active ulcerative colitis, according to a company press release.
The expanded use, according to the release, is for patients who have had an inadequate response with, lost response to, or were intolerant to either conventional or biologic therapies, or have medical contraindications to those therapies.
“The devastating impact of ulcerative colitis on the lives of people with this condition is often underestimated,” Silvio Danese, MD, PhD, head of the Inflammatory Bowel

Source link

Related posts

Ranking for Abdominal Surgeries Not Linked to Patient Outcomes


CMS aims to increase drug pricing transparency through price disclosure legislation


Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World